These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10024837)

  • 21. The safety profile of quinapril: is there a difference among ACE inhibitors?
    Canter D; Frank GJ; Knapp LE; McLain RW
    Clin Cardiol; 1990 Jun; 13(6 Suppl 7):VII39-42. PubMed ID: 2189620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The response to the first dose of an angiotensin converting enzyme inhibitor in uncomplicated hypertension--a placebo controlled study utilising ambulatory blood pressure recording.
    MacFadyen RJ; Bainbridge AD; Lees KR; Reid JL
    Br J Clin Pharmacol; 1991 Sep; 32(3):393-8. PubMed ID: 1777377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet function during antihypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor.
    Gupta RK; Kjeldsen SE; Motley E; Weder AB; Zweifler AJ; Julius S
    J Cardiovasc Pharmacol; 1991 Jan; 17(1):13-9. PubMed ID: 1708046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension.
    Lenz T; Schulte KL; Wagner B; Lilienthal J; Gotzen R
    Eur Heart J; 1994 Jul; 15(7):940-6. PubMed ID: 7925516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quinapril: a double-blind, placebo-controlled trial in essential hypertension.
    Maclean D
    Angiology; 1989 Apr; 40(4 Pt 2):370-81. PubMed ID: 2650581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of quinapril and its active metabolite quinaprilat during continuous ambulatory peritoneal dialysis.
    Swartz RD; Starmann B; Horvath AM; Olson SC; Posvar EL
    J Clin Pharmacol; 1990 Dec; 30(12):1136-41. PubMed ID: 2273086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinapril versus enalapril in the treatment of mild-to-moderate essential hypertension.
    Sánchez S; Luna A; Orozco R; Velasco G
    Clin Ther; 1991; 13(5):651-5. PubMed ID: 1799922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril.
    Materson BJ
    Am J Cardiol; 1992 Apr; 69(10):46C-53C. PubMed ID: 1546639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The treatment of moderate to severe hypertension with ACE inhibitors.
    Goldstein RJ
    J Cardiovasc Pharmacol; 1990; 15 Suppl 2():S29-35. PubMed ID: 1691404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The safety and tolerability of quinapril.
    Knapp LE; Frank GJ; McLain R; Rieger MM; Posvar E; Singer R
    J Cardiovasc Pharmacol; 1990; 15 Suppl 2():S47-55. PubMed ID: 1691407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure.
    Riegger GA
    Eur Heart J; 1991 Jun; 12(6):705-11. PubMed ID: 1830551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension: the Quinapril Titration Interval Management Evaluation (ATIME) Study. ATIME Research Group.
    Flack JM; Yunis C; Preisser J; Holmes CB; Mensah G; McLean B; Saunders E
    Arch Intern Med; 2000 Jun; 160(12):1842-7. PubMed ID: 10871979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quinapril and hydrochlorothiazide combination for control of hypertension: assessment by factorial design. Quinapril Investigator Group.
    Canter D; Frank GJ; Knapp LE; Phelps M; Quade M; Texter M
    J Hum Hypertens; 1994 Mar; 8(3):155-62. PubMed ID: 8006914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of incipient glomerular lesions in experimental diabetic nephropathy by hypotensive and subhypotensive dosages of an ACE inhibitor.
    Fabris B; Candido R; Carraro M; Fior F; Artero M; Zennaro C; Cattin MR; Fiorotto A; Bortoletto M; Millevoi C; Bardelli M; Faccini L; Carretta R
    Diabetes; 2001 Nov; 50(11):2619-24. PubMed ID: 11679443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A postmarketing surveillance evaluation of quinapril in 3742 Canadian hypertensive patients: the ACCEPT Study. Accupril Canadian Clinical Evaluation and Patient Teaching.
    Larochelle P; Haynes B; Maron N; Dugas S
    Clin Ther; 1994; 16(5):838-53. PubMed ID: 7859244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The Study Group of Quinapril in Arterial Hypertension. The Steering Committee].
    Ambrosioni E; Brusca A; Caponnetto S; Condorelli M; Corea L; Dal Palù C; Fogari R; Mameli P; Mancia G; Neri Serneri GG
    Minerva Cardioangiol; 1992 Mar; 40(3):85-96. PubMed ID: 1630680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Life-threatening postoperative angioedema following treatment with an angiotensin converting enzyme inhibitor].
    Maier C
    Anaesthesist; 1995 Dec; 44(12):875-9. PubMed ID: 8594963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quinapril. A review of its pharmacological properties, and therapeutic efficacy in cardiovascular disorders.
    Wadworth AN; Brogden RN
    Drugs; 1991 Mar; 41(3):378-99. PubMed ID: 1711445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients.
    Hausberg M; Barenbrock M; Hohage H; Müller S; Heidenreich S; Rahn KH
    Hypertension; 1999 Mar; 33(3):862-8. PubMed ID: 10082500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Albumin excretion rate and metabolic modifications in patients with essential hypertension. Effects of two angiotensin converting enzyme inhibitors.
    Puig JG; Mateos FA; Ramos TH; Lavilla MP; Capitán MC; Gil A
    Am J Hypertens; 1994 Jan; 7(1):46-51. PubMed ID: 8136110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.